Share on StockTwits

Stock analysts at Leerink Swann increased their price target on shares of Dyax Corp. (NASDAQ:DYAX) from $8.00 to $12.00 in a report issued on Wednesday, Analyst RN reports. The firm currently has a “market perform” rating on the stock. Leerink Swann’s price objective indicates a potential upside of 10.91% from the company’s current price.

In other Dyax Corp. news, VP Andrew Ashe sold 2,723 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $10.10, for a total transaction of $27,502.30. Following the sale, the vice president now directly owns 12,277 shares of the company’s stock, valued at approximately $123,998. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Dyax Corp. (NASDAQ:DYAX) traded down 7.35% on Wednesday, hitting $10.025. The stock had a trading volume of 846,910 shares. Dyax Corp. has a 52 week low of $2.26 and a 52 week high of $10.99. The stock’s 50-day moving average is $8.94 and its 200-day moving average is $7.26. The company’s market cap is $1.214 billion.

Several other analysts have also recently commented on the stock. Analysts at Needham & Company raised their price target on shares of Dyax Corp. from $7.50 to $13.00 in a research note on Tuesday, February 18th. They now have a “buy” rating on the stock. Analysts at Wedbush initiated coverage on shares of Dyax Corp. in a research note on Monday, January 13th. They set an “outperform” rating and a $11.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Dyax Corp. presently has an average rating of “Buy” and a consensus target price of $12.00.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.